Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal ad… Read more
Panbela Therapeutics Inc (PBLA) - Total Assets
Latest total assets as of September 2024: $5.17 Million USD
Based on the latest financial reports, Panbela Therapeutics Inc (PBLA) holds total assets worth $5.17 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panbela Therapeutics Inc - Total Assets Trend (2011–2023)
This chart illustrates how Panbela Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panbela Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Panbela Therapeutics Inc's total assets of $5.17 Million consist of 25.9% current assets and 74.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.8% |
| Accounts Receivable | $183.00K | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2023)
This chart illustrates how Panbela Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panbela Therapeutics Inc's current assets represent 25.9% of total assets in 2023, a decrease from 96.1% in 2011.
- Cash Position: Cash and equivalents constituted 21.8% of total assets in 2023, up from 18.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Panbela Therapeutics Inc Competitors by Total Assets
Key competitors of Panbela Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Panbela Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Panbela Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Panbela Therapeutics Inc is currently not profitable relative to its asset base.
Panbela Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 0.21 | 1.76 |
| Quick Ratio | 0.26 | 0.21 | 1.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.97 Million | $ -7.03 Million | $ 1.33 Million |
Panbela Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Panbela Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.22 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 137.1% |
| Total Assets | $11.80 Million |
| Market Capitalization | $1.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values Panbela Therapeutics Inc's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Panbela Therapeutics Inc's assets grew by 137.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Panbela Therapeutics Inc (2011–2023)
The table below shows the annual total assets of Panbela Therapeutics Inc from 2011 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $11.80 Million | +137.08% |
| 2022-12-31 | $4.98 Million | -61.33% |
| 2021-12-31 | $12.87 Million | +31.17% |
| 2020-12-31 | $9.81 Million | +212.12% |
| 2019-12-31 | $3.14 Million | +65.65% |
| 2018-12-31 | $1.90 Million | +147.46% |
| 2017-12-31 | $767.00K | -12.54% |
| 2016-12-31 | $877.00K | -51.49% |
| 2015-12-31 | $1.81 Million | +344.10% |
| 2014-12-31 | $407.12K | -23.51% |
| 2013-12-31 | $532.26K | -12.87% |
| 2012-12-31 | $610.91K | +140.72% |
| 2011-12-31 | $253.79K | -- |